Our Pipeline


We develop a broad portfolio of drug candidates that have the potential to meaningfully improve the lives of patients by directly addressing the causes and risk factors of neurodegenerative diseases.

Each of our programs strictly follows the principles of our R&D strategy: Selecting targets that are genetically linked to the disease, engineering our molecules to cross the blood-brain barrier, and guiding clinical development through the discovery and use of biomarkers.

Our Pipeline

Lysosomal Function
Target Indication Drug Candidate
LRRK2 Parkinson's Early Clinical Early Clinical DNL201
LRRK2 Parkinson's Early Clinical Early Clinical DNL151
Iduronate 2-sulfatase MPS II (Hunter Syndrome) IND-Enabling IND-Enabling DNL310 (ETV:IDS)
Alpha-Synuclein Parkinson's, DLB, MSA IND-Enabling IND-Enabling ATV:aSyn
Undisclosed Neurodegeneration Drug Discovery Drug Discovery LF1
Undisclosed Lysosomal storage disease with Neurodegeneration Drug Discovery Drug Discovery ETV:LF2
Undisclosed Lysosomal storage disease with Neurodegeneration Drug Discovery Drug Discovery ETV:LF3
Drug Discovery IND-Enabling Early Clinical Late Clinical Approved
Glial Biology
Target Indication Drug Candidate
RIPK1 ALS, Alzheimer's, MS Early Clinical Early Clinical DNL747
TREM2 Alzheimer's Drug Discovery Drug Discovery ATV:TREM2
Undisclosed Alzheimer's Drug Discovery Drug Discovery GB1
Drug Discovery IND-Enabling Early Clinical Late Clinical Approved
Cellular Homeostasis
Target Indication Drug Candidate
EIF2B ALS, FTD IND-Enabling IND-Enabling DNL343
Tau Alzheimer's Drug Discovery Drug Discovery ATV:Tau
Undisclosed ALS, Alzheimer's Drug Discovery Drug Discovery CH1
Undisclosed ALS, Parkinson's Drug Discovery Drug Discovery CH2
Drug Discovery IND-Enabling Early Clinical Late Clinical Approved
Other
Target Indication Drug Candidate
RIPK1 RA, Peripheral Inflammatory Disease Early Clinical Early Clinical DNL758
Undisclosed Undisclosed Drug Discovery Drug Discovery OT1
Undisclosed Undisclosed Drug Discovery Drug Discovery OT2
Drug Discovery IND-Enabling Early Clinical Late Clinical Approved
Patients